Roy Baynes, M.D., Ph.D., has been a member of the board of directors of Travere Therapeutics, Inc. since 2016. He has served as senior vice president and head of Global Clinical Development at Merck Research Laboratories, the research division of Merck and Co., Inc., since December 2013 and as chief medical officer of Merck and Co, Inc., a global healthcare company, since July 2016. As of April 1, 2022, he has stepped down as head of Global Clinical Development and as chief medical officer and will retire from Merck in early July 2022. In March 2022 he was appointed, to be effective July 11, 2022, executive vice president and chief medical officer of Eikon Therapeutics, Inc. a privately-held biotechnology company. Prior to his role at Merck, Dr. Baynes was senior vice president of oncology, inflammation and respiratory therapeutics at Gilead Sciences, Inc., which was preceded by his service at Amgen, Inc. as vice president of global clinical development and therapeutic area head for hematology/oncology. Before joining Amgen, Dr. Baynes was the Charles Martin Professor of Cancer Research at the Barbara Ann Karmanos Cancer Institute, a National Cancer Institute-designated Comprehensive Cancer Center, at Wayne State University. Dr. Baynes has authored more than 150 publications and is a member or fellow of several international medical societies. Dr. Baynes received his medical degree and doctorate in philosophy from the University of the Witwatersrand in South Africa, and completed his medical training in the Department of Hematology and Oncology at Johannesburg Hospital.
© 2022 Travere Therapeutics, Inc. All rights reserved. For US audiences. Chenodal®, Cholbam® and Total Care HUB® are registered trademarks of Travere Therapeutics, Inc. Thiola® and Thiola EC® are registered trademarks of Mission Pharmacal Company.